Global Variability in Reported Mortality for Critical Illness during the 2009-10 Influenza A(H1N1) Pandemic: A Systematic Review and Meta-Regression to Guide Reporting of Outcomes during Disease Outbreaks

Abhijit Duggal1,2*, Ruxandra Pinto3, Gordon Rubenfeld1,3,4, Robert A. Fowler1,3,4
1 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada, 2 Department of Critical Care, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, United States of America, 3 Trauma, Emergency and Critical Care Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, 4 Interdepartmental Division of Critical Care and Department of Medicine, University of Toronto, Toronto, Ontario, Canada

* Duggala2@ccf.org

Abstract

Purpose
To determine how patient, healthcare system and study-specific factors influence reported mortality associated with critical illness during the 2009–2010 Influenza A (H1N1) pandemic.

Methods
Systematic review with meta-regression of studies reporting on mortality associated with critical illness during the 2009–2010 Influenza A (H1N1) pandemic.

Data Sources
Medline, Embase, LiLACs and African Index Medicus to June 2009-March 2016.

Results
226 studies from 50 countries met our inclusion criteria. Mortality associated with H1N1-related critical illness was 31% (95% CI 28–34). Reported mortality was highest in South Asia (61% [95% CI 50–71]) and Sub-Saharan Africa (53% [95% CI 29–75]), in comparison to Western Europe (25% [95% CI 22–30]), North America (25% [95% CI 22–27]) and Australia (15% [95% CI 13–18]) (P<0.0001). High income economies had significantly lower reported mortality compared to upper middle income economies and lower middle income economies respectively (P<0.0001). Mortality for the first wave was non-significantly higher than wave two (P = 0.66). There was substantial variability in reported mortality among the specific subgroups of patients: unselected critically ill adults (27% [95% CI 24–30]), acute
respiratory distress syndrome (37% [95% CI 32–44]), acute kidney injury (44% [95% CI 26–64]), and critically ill pregnant patients (10% [95% CI 5–19]).

**Conclusion**

Reported mortality for outbreaks and pandemics may vary substantially depending upon selected patient characteristics, the number of patients described, and the region and economic status of the outbreak location. Outcomes from a relatively small number of patients from specific regions may lead to biased estimates of outcomes on a global scale.

**Introduction**

Mortality and morbidity associated with viral outbreaks is a major public health concern. With globalization, and increasing ease of travel these outbreaks have a higher likelihood to spread quickly and become significant global health threats. [1–4] The 2009–2010 Influenza A (H1N1) outbreak was declared the first pandemic of this century after early reports of high morbidity and mortality and subsequent imported cases and sustained transmission in many countries. [5–7]

Early outbreak reporting informs expectations in morbidity, mortality and guides health systems’ response, to specific outbreaks. [5, 6] This reporting is instrumental for public health risk assessments. [8] However, detection bias towards identification and inclusion of the sickest patients and selection bias (of specific sub-groups of patients) are substantial threats to the internal validity and generalizability for early outbreak studies. [9–11] As well, there may be unique geographic or socioeconomic characteristics of the first affected regions that influence patient outcomes. [5] Oftentimes, there is incomplete reporting of the entire outbreak period and population, leading to inaccurate estimates for future events.

The H1N1 pandemic was unique as it was the first instance of a pandemic that was widely reported over different geographical and socioeconomic strata at a global level during 2009–2010. [2, 12] However, influenza A (H1N1) comprised the majority of global seasonal influenza-related illness again in 2013–2014. [13] With this in mind, we performed a systematic review of all studies describing critically ill patients in the 2009–2010 Influenza A (H1N1) outbreak in order to better understand how patient, temporal, healthcare system and study-specific factors influence reporting of clinical outcomes and to attempt to provide unbiased and valid estimates of mortality. We deliberately did not focus upon all patients with H1N1 as there is no globally valid denominator to describe these patients over different geographic regions. Thus using a standardized definition of critical illness we included such patients across different geographic regions and time periods. Moreover, a focus on critically ill patients is clinically relevant as they are most likely to have poor outcomes and therefore represent an important group to target for early prediction and care.

**Methods**

**Search Strategy**

We searched Medline (January week 1, 2009 to March week 2, 2016), Embase Classic + Embase (2009 week 1 to 2016 week 10), LILACS and African Index Medicus for studies that evaluated mortality associated with critical illness in confirmed, probable or suspected cases of 2009–2010 Influenza A (H1N1) infection (for detailed search strategy see S1 File). We reviewed the
references of all retrieved studies and reviews to identify any additional studies. We considered full text articles published in any language. We did not consider abstracts or other material presented at medical conferences or unpublished data. The research and ethics committee of our institution waived the need for patient-level consent for this study as only aggregate and previously published data was collected.

Study Selection

Inclusion Criteria: (1) described confirmed, probable or suspected cases of 2009–2010 influenza A (H1N1) infection; and (2) described patient(s) who were critically ill (admission to an adult or pediatric intensive care unit (ICU) or area of the hospital where critically ill patients routinely receive treatment; or, patients receiving invasive or non-invasive mechanical ventilation; or, patients receiving continuous intravenous vasoactive medications; or, other criteria with justification presented in the individual study to designate patients as critically ill). Exclusion Criteria: (1) case series describing fewer than 5 patients; (2) studies that did not report mortality in critically ill patients, or only described characteristics of patients who died. Fig 1 outlines the study flow diagram based on PRISMA guidelines. [14] We anticipated that many early and potentially smaller studies would describe patients subsequently included in multicenter or national studies. To prevent non-independent reporting, we included studies only representing non-overlapping patient populations for the description of outcomes over different geographical or economic regions and specific ICU populations; however we included studies with potentially duplicated patients for description of outcomes over time, and for single versus multiple centers comparisons (Inclusion criteria for subgroups described in S1 File; Fig A in S1 File).

Objectives

The primary objective was to determine mortality of critically ill patients with Influenza A (H1N1) during the 2009–2010 pandemic. We preferentially used hospital, then 1 month, then in-ICU mortality, whichever represented the longest period of follow-up in order to obtain the least time-biased estimate. Our secondary objective was to determine how study, healthcare system and patient-associated factors influence reporting of mortality.

Data Extraction

Study characteristics and key results were abstracted by one author (AD) using a standardized study report form. The primary outcome was abstracted in duplicate from all studies by a second author (RF) to ensure a high degree of inter-rater reliability. We collected geographic (country, hemisphere, region and continent) variables and economic (World Bank designation) designation for each country [15]; whether the study included unselected (consecutive) or selective (non-consecutive) critically ill patients, or specific patient populations (e.g. adults and separately pediatric patients, only mechanically ventilated patients, only patients receiving rescue oxygenation therapy, only those with specific organ injury such as acute respiratory distress syndrome [ARDS] or acute renal injury); the duration of the study (based on the months and year of inclusion of the first and last patients of the study) and also whether the study period reported on the region-specific first wave, second wave, third wave or more than one wave of the pandemic.

We collected patient demographics reported in aggregate, severity of illness using the Acute Physiology and Chronic Health Evaluation (APACHE) II/III/IV, Pediatric Risk of Mortality (PRISM) II/III, sequential organ failure assessment (SOFA) or Simplified Acute Physiology Score (SAPS)II/III; age (overall, and among adults and children <18 years); sex; co-morbidities
Flowchart of studies included in the systematic review using PRISMA guidelines

Records identified through database searching
(Medline-4112
EMBASE-3535)
LILACS-31
African Index Medicus-33)

Records after duplicates removed
(n = 5653)

Additional records identified through references of included articles and review articles
(n = 27)

Records excluded upon screening
(n = 5207)
Critically ill patients not described: 2704
No clinical outcomes of interest described: 1618
Conference abstracts: 478
Reviews: 407

Full-text articles assessed for eligibility
(n = 446)

Full-text articles excluded, with reasons
(n = 226)
Outcome of interest not reported: 64
Critically ill patients not described: 49
Only fatal Cases reported: 25
Review Article: 19
Case Report: 14
Other Reasons: 56

Articles included in qualitative synthesis
220 studies

Fig 1. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram. Study identification and selection process.
doi:10.1371/journal.pone.0155044.g001
Table 1. System and study based characteristics described in 226 studies compared to the studies selected for the meta-regression and hierarchical model respectively.

| Study Characteristics                                                                 | All Studies (n=226) |
|---------------------------------------------------------------------------------------|---------------------|
| Period of Enrollment                                                                  |                     |
| April 2009-August 2009                                                                | 50 (22%)            |
| September 2009-January 2010                                                          | 31 (14%)            |
| February 2010 until end of pandemic                                                   | 3 (1%)              |
| Studies enrolling through different waves of the pandemic                             | 144 (63%)           |
| Multicenter Studies                                                                   | 109 (49%)           |
| Study size (number of patients)                                                       |                     |
| 5–10                                                                                  | 36 (16%)            |
| 11–25                                                                                 | 79 (35%)            |
| 26–100                                 | 68 (30%)            |
| 101–250                                | 22 (10%)            |
| >250                                   | 21 (9%)             |
| Studies with only adult patients                                                     | 140 (63%)           |
| Studies describing unselected critically ill patients                                | 155 (69%)           |
| Studies describing specific subgroups                                                 |                     |
| Mechanical ventilation                                                               | 63 (28%)            |
| ARDS                                    | 59 (26%)            |
| Acute kidney injury                                                                  | 10 (4%)             |
| Pregnant critically ill                                                              | 8 (4%)              |
| ECMO                                    | 20 (9%)             |
| Study geographical region                                                            |                     |
| Americas                                                                              |                     |
| North America*                                                                        | 43 (19%)            |
| Latin America and Caribbean                                                         | 26 (11%)            |
| Europe                                  |                     |
| Western Europe                                                                       | 69 (31%)            |
| Eastern Europe                                                                       | 11 (5%)             |
| Asia                                    |                     |
| Middle East                                                                           | 12 (5%)             |
| South Asia                                                                           | 12 (5%)             |
| East Asia and Pacific                                                                | 32 (14%)            |
| Africa                                  |                     |
| North Africa                                                                         | 3 (1%)              |
| Sub-Saharan Africa                                                                   | 3 (1%)              |
| Australia/New Zealand                                                               | 16 (7%)             |
| Study country economic status of the country                                         |                     |
| High income economy                                                                  | 161 (71%)           |
| Upper middle income economy                                                          | 50 (22%)            |
| Lower middle income economy                                                          | 13 (6%)             |

Values are numbers (percentages) unless stated otherwise. We describe the system based, temporal and geographical characteristics of countries included in our systematic review. We also describe similar variables for studies included in our meta-regression and our hierarchical model. This table shows that at each level the relative distribution of the variables remained constant throughout the reported studies.

*Mexico is analyzed separately from United States and Canada and is considered to be a part of Latin America and Caribbean according to World Bank geographical regions. ARDS: Acute Respiratory Distress Syndrome; ECMO: Extracorporeal Membrane Oxygenation

doi:10.1371/journal.pone.0155044.t001
including obesity, diabetes, congestive heart failure, cerebrovascular disease, neoplastic disorders, chronic liver, or renal diseases; and the presence of immunosuppression; and, co-presenting conditions such as pregnancy or post-partum status (detailed definitions of all variables provided in S1 File).

Quality Assessment

We used the Newcastle-Ottawa scale to assess study quality. [16, 17] The scale allocates up to 9 points to evaluate the risk of bias (higher scores indicate a smaller likelihood of bias) in cohort or case-control studies in 3 domains: selection of study groups (4 points), comparability of groups (2 points), and ascertainment of either exposure or outcome (3 points). As we were not comparing two distinct groups of patients we evaluated the risk for under- or over-reporting of mortality based on the three domains of the scale. We used a modified Newcastle-Ottawa Scale to assess the appropriateness of selection, and follow up of these patients and defined the risk as being high for studies with a score of 6 or lower.

Statistical Analysis

We combined data from studies to estimate the pooled risk for death. We explored clinical heterogeneity by establishing subgroups of studies according to distinct patient populations and determined statistical heterogeneity among studies by using the Q statistic and I² index. [18] We used a random effects model to obtain summary outcome point estimates and 95% confidence intervals. [19]

We conducted random effects meta-regression analyses for mortality for different variables extracted from the studies, including specific pandemic time periods (first wave, second wave, prolonged enrollment), geographical region (country, region, continent, World Bank economic development status), study population characteristics (unselected vs. selected patient populations, mechanically ventilated vs. not ventilated patients) and patient population factors (adults, children), pregnancy or post-partum state, specific illnesses (ARDS, acute kidney injury) and ICU specific interventions such as receipt of rescue oxygenation therapy (extracorporeal membrane oxygenation (ECMO), high frequency oscillatory ventilation (HFOV)). We also performed a paired analysis for all the countries that reported mortality both during Wave I of the pandemic as well as enrolled for longer than nine months. [20, 21] [22] Risk of publication bias was assessed with a funnel plot, Trim and fill method was used to identify and correct for funnel plot asymmetry. Meta-analysis and meta-regression exploring the influence of patient, study and health system factors on reported mortality was conducted on the logit transformed proportions. Analyses were performed using R version 3.2.5 and SAS version 9.4 (SAS Institute, Cary, NC).

Results

Study Flow

Our search strategy yielded 5653 citations after de-duplication. We retrieved 446 articles for a detailed evaluation and included 220 articles for our qualitative assessment. We identified 226 studies from 220 articles (six of the articles compared two different time periods of the pandemic and were thus reported separately) from 50 countries that met our inclusion criteria (Table 1). 115 studies with non-overlapping patients were used in the different meta-regression subgroups.
Study Characteristics

The study characteristics were similar when combined for both the meta-regression and the hierarchical meta-regression (Table A in S1 File). There was no clinically important difference in the reporting of demographic, and intervention variables among populations when we evaluated all included studies compared to studies only included in the meta-regression (Table 2). Median age of patients was 40 (32–44) years, 49% were female. Among the 89 (39%) studies, which reported APACHE II scores, the median APACHE II was 18 (14–21). 132 (58%) studies reported on the incidence of ARDS, and the median incidence of ARDS was 95% among those studies.

Risk of Bias and quality of evidence assessment

We did not identify any randomized controlled trials; therefore, only observational studies (cohort, case-control) were included in our analysis. The median Newcastle-Ottawa Scale score was 7 (range 4–9). Most studies were considered to be of high quality (Table B in S1 File). The funnel plot displayed visual asymmetry (Fig B in S1 File) and the trim and fill analysis estimated 15 missing studies. (Fig C in S1 File) Based on the Egger’s classical test (p = 0.026) the publication bias was statistically significant.

Table 2. Description of patient characteristics, intensive care specific interventions and outcomes from included studies compared to the studies selected for the meta-regression respectively.

| Characteristics             | All studies (n = 226) | Studies for meta-regression (n = 115) |
|-----------------------------|-----------------------|--------------------------------------|
|                             | N                     | Median (IQR), Proportion             | N                     | Median (IQR), Proportion             |
| Age                         | 179                   | 40 (32–44)                           | 88                    | 42 (37–46)                           |
| Females                     | 177                   | 49%                                  | 89                    | 49%                                  |
| APACHE II                   | 89                    | 18 (14–21)                           | 44                    | 17 (14–19)                           |
| Pre-existing lung disease   | 144                   | 26%                                  | 74                    | 25%                                  |
| Obesity                     | 102                   | 29%                                  | 62                    | 27%                                  |
| Pregnancy                   | 103                   | 9%                                   | 59                    | 9%                                   |
| ICU Complications           |                       |                                      |                       |                                       |
| ARDS                        | 132                   | 95%                                  | 74                    | 98%                                  |
| Acute renal failure         | 49                    | 36%                                  | 25                    | 39%                                  |
| ICU Treatments              |                       |                                      |                       |                                       |
| Renal replacement therapy   | 63                    | 17%                                  | 35                    | 16%                                  |
| Inotropes                   | 98                    | 50%                                  | 47                    | 51%                                  |
| Antivirals                  | 92                    | 100%                                 | 53                    | 100%                                 |
| Antibiotics                 | 49                    | 100%                                 | 27                    | 100%                                 |
| Corticosteroids             | 70                    | 48%                                  | 32                    | 52%                                  |
| Outcomes                    |                       |                                      |                       |                                       |
| Duration of mechanical ventilation | 74                    | 10 (8–14)                           | 38                    | 10 (7–14)                           |
| ICU length of stay          | 99                    | 11 (8–18)                           | 49                    | 11 (8–20)                           |
| Mortality*                  | 226                   | 28%                                  | 115                   | 32%                                  |

Categorical variables are described as numbers (percentages) and continuous variables are described as median (interquartile range) unless stated otherwise. N Denotes the number of studies that reported on each variable. The reporting of patient level variables remained similar at all levels of our analysis of the reported studies. APACHE II: Acute Physiology and Chronic Health Evaluation II; ARDS: Acute Respiratory Distress Syndrome; ICU: Intensive Care Unit.

*The mortality described is a mean of all studies reporting short term mortality associated with critical illness during the H1N1 pandemic

doi:10.1371/journal.pone.0155044.t002
Meta-Regression of reported mortality during the 2009 Influenza A (H1N1) pandemic

After excluding duplicate studies and those reporting exclusively on pediatric patients we extracted data from 115 studies to report on the mortality associated with specific subgroups of patients.

Reported mortality over time

14 studies reported during the first wave of the pandemic, and 20 studies reported on the second wave. Nineteen manuscripts described patients over a prolonged period of time (>9 months). Overall mortality was 31% among adult patients. Mortality for the first wave of the H1N1 pandemic was 39% (95% CI 33–45), 30% (95% CI 23–39) in wave 2, and 31% (95% CI 25–36) during prolonged enrollment (p = 0.66). (Fig 2) When analyses was restricted to those countries that reported on early as well as prolonged periods of time from within the same country, there was no difference in mortality. (Table 3)

| Subgroup                        | Studies (N) | Deaths (N) | Patients (Total, N) | Proportion Dead (95% CI) | p-value | I-squared |
|---------------------------------|-------------|------------|---------------------|--------------------------|---------|-----------|
| Time                            |             |            |                     |                          |         |           |
| Wave 2                          | 20          | 256        | 941                 | 30.1 [22.8, 38.6]        |         | 64.1%     |
| Prolonged                       | 20          | 1091       | 4071                | 30.6 [25.4, 36.3]        |         | 85.1%     |
| Wave 1                          | 14          | 266        | 620                 | 38.7 [32.6, 45.2]        |         | 51.0%     |
| Geographical Region             |             |            |                     |                          | <0.0001 |           |
| Australia                       | 2           | 184        | 1204                | 15.1 [12.6, 17.9]        |         | 67.6%     |
| North America                   | 12          | 833        | 3399                | 24.5 [21.9, 27.2]        |         |           |
| West Europe                     | 40          | 875        | 3608                | 25.6 [21.7, 29.9]        |         |           |
| East Asia and Pacific           | 17          | 224        | 840                 | 27.6 [22.9, 32.9]        |         |           |
| Middle East and North Africa    | 9           | 73         | 222                 | 33.8 [27.7, 40.4]        |         |           |
| Eastern Europe                  | 10          | 111        | 309                 | 34.4 [25.4, 44.8]        |         |           |
| Latin America and Caribbean     | 14          | 327        | 800                 | 38.6 [22.2, 45.4]        |         |           |
| Sub-Saharan Africa              | 3           | 21         | 39                  | 53.7 [26.2, 79.2]        |         |           |
| South Asia                      | 8           | 164        | 274                 | 60.9 [49.6, 71.2]        |         |           |
| World Bank Economic Development Status |       |            |                     |                          | <0.0001 | 75.6%     |
| High income Economy             | 75          | 2143       | 9066                | 26.0 [23.6, 28.6]        |         |           |
| Upper Middle income Economy     | 31          | 495        | 1335                | 36.7 [31.3, 42.4]        |         |           |
| Lower Middle income Economy     | 9           | 170        | 294                 | 57.6 [45.8, 69.5]        |         |           |
| Adults vs Pediatrics            |             |            |                     |                          | <0.0001 |           |
| Pediatrics                      | 20          | 130        | 799                 | 13.6 [9.2, 20.2]         |         | 83.9%     |
| Adults                          | 81          | 1673       | 6641                | 29.6 [26.2, 33.2]        |         | 74.8%     |
| Both Adults and Pediatrics      | 31          | 1116       | 4007                | 32.7 [28.1, 37.6]        |         | 82.8%     |
| Multi vs Single                 |             |            |                     |                          | 0.3741  | 84.6%     |
| Multicenter                     | 46          | 2366       | 9339                | 29.5 [26.3, 32.7]        |         |           |
| Single                          | 69          | 446        | 1356                | 32.2 [27.9, 36.7]        |         |           |
| Number of patients              |             |            |                     |                          | 0.2857  | 83.9%     |
| >250                            | 10          | 1683       | 7090                | 24.3 [19.3, 30.1]        |         |           |
| 101-250                         | 6           | 278        | 981                 | 28.0 [19.1, 38.9]        |         | 91.1%     |
| 26-100                          | 30          | 515        | 1810                | 30.9 [25.7, 36.5]        |         | 79.9%     |
| 11-25                           | 46          | 279        | 842                 | 33.4 [28.9, 38.3]        |         | 46.5%     |
| <=10                            | 23          | 67         | 172                 | 37.2 [29.6, 45.4]        |         | 0.0%      |
| Overall (no pediatrics)         | 115         | 2812       | 10695               | 30.9 [28.2, 33.7]        |         | 82.2%     |

Fig 2. Reported mortality associated with 2009 Influenza A (H1N1) associated critical illness. We describe the mortality based on temporal (early, late and prolonged enrollment), study (study size, single center compared to multicenter and adults compared to pediatrics), and the geographic location and socioeconomic development from the included studies. The black squares represent the point estimate and 95% confidence intervals (CIs) around the mortality for each subgroup. The black diamond is the summary or overall combined estimate of mortality associated with the 2009 Influenza A (H1N1) pandemic.

doi:10.1371/journal.pone.0155044.g002
Global Variability in Reported Mortality for Critical Illness during the 2009-10 H1N1 Pandemic

System-based Variables

Geographical area of the study. There was no difference in the mortality based on studies from northern hemisphere (31% [95% CI 28–34]) compared to the southern hemisphere (33% [95% CI 24–44]); however, we found significant differences among different continents and geographical regions (Fig 3). Continental mortality reported from Australia was lowest (15% [95% CI 13–18]), from Africa the highest (42% [95% CI 23–64]), from Asia 37% (95% CI 31–44), South America (36% [95% CI 29–45]), North America 27% (95% CI 24–32), and Europe 27% (95% CI 23–31). When we compared the reported mortality based on the geographical region mortality was the highest in the South Asian (61% [95% CI 50–71]) and Sub-Saharan African (53% [95% CI 29–75]) countries. Mortality was comparable in North America (25% [95% CI 22–27]); West Europe (25% [95% CI 22–30]) and East Asia and Pacific 28% [95% CI 23–33). Reported mortality in Middle Eastern and North African countries (34% [95% CI 28–40]), Eastern European (35% [95% CI 26–47]), and Latin American Countries (39% [95% CI 32–45]) all showed a more pronounced effect when the geographical region rather than the hemisphere or the continent was considered.

Economic status of the country. High income economies had significantly lower reported mortality (26% [95% CI 24–29] compared to upper middle income economies (37 [95% CI 31–42]) and lower middle income economies (58% [95% CI 46–69]) respectively (P<0.0001). (Fig 3) There were clinically relevant differences in the duration of mechanical ventilation among studies from high income economies (11[8–16] days) compared to upper (9 [8–10] days) and lower (8 [6–10] days) middle income economies but not in ICU length of stay (Table B in S1 File).

Table 3. Meta-analysis comparing the reported mortality from “early enrollment” (the Wave 1 for each individual country) during the H1N1 pandemic with studies describing prolonged enrollment from the same countries. We evaluated the differences in the reported mortality among studies from individual countries by using both a fixed-effects and a random-effects model.

| Country               | Relative Risk (95% CI) |
|-----------------------|------------------------|
| Australia/ New Zealand| 1.09 (0.87–1.36)       |
| Canada                | 1.27 (0.89–1.82)       |
| China                 | 1.3 (1.01–1.68)        |
| France                | 2.66 (0.89–7.9)        |
| Italy                 | 1.003 (0.28–3.53)      |
| Mexico                | 0.85 (0.42–1.74)       |
| Spain                 | 0.84 (0.45–1.55)       |
| USA                   | 0.77 (0.51–1.16)       |
| Random Effects Model  | 1.11 (0.93–1.31)       |
|                       | p-value = 0.23         |
| Quantification of Heterogeneity | Q = 8.92 |
| Test of Heterogeneity | I² = 21.6% (0%–64%)    |
|                       | d.f = 7                |
|                       | p-value = 0.26         |

The table shows that at an individual country level, the relative risk of death was not statistically significantly different during the duration of the pandemic. The reporting from early case-series gave an approximate estimate of the overall mortality in any given country though the entirety of a pandemic. However, we also found that there were significant intra-country differences in the reported mortality among different countries, and these differences also tended to remain constant when they are studied through the entirety of the pandemic.

doi:10.1371/journal.pone.0155044.t003
Patient-related Factors

**Age.** Mortality was significantly lower in the pediatric studies (14% [95% CI 9–20]) compared to the adult studies (30% [95% CI 26–33]) (P<0.0001) in unselected critically ill patients.

**Specific patient populations.** Mortality was substantially higher among patients undergoing mechanical ventilation (42% [95% CI 36–49]) in comparison to unselected critically ill patients, (27% [95% CI 24–30]) (Fig 4). Mortality in patients with ARDS was 37% (95% CI 32–44) and 44% [95% CI 26–64] among critically ill patients with acute kidney injury, and 10% (95% CI 5–19) among critically ill pregnant patients (Fig 4; Table C in S1 File).

**Discussion**

In this systematic review and meta-regression of 226 studies investigating pandemic influenza A (H1N1)-related critical illness from 50 countries, we found that overall adult mortality was 31%. There was substantial variability in mortality according to the global region and the country’s economic development status—mortality in sub-Saharan Africa and South Asia was double that of Australia, North America and Western Europe. Studies of specific populations and those from early in the pandemic were smaller, clinically more heterogeneous and had a higher
reported mortality. There were significant differences in reported mortality based on the severity of illness. The need for mechanical ventilation and critical illness associated acute kidney injury were most strongly associated with higher reported mortality at a global level.

These findings are important because they emphasize that patient specific factors such as organ failure or need for artificial life support, along with geographic area or economic development of a country from which these events are being reported can have a significant influence on the reported mortality during disease outbreaks. These findings highlight the limitations to generalizing early reported outcomes from a limited region and among a relatively small number of patients and have relevance for contemporary outbreaks such seasonal and avian influenza, Middle East Respiratory Syndrome Coronavirus and Ebola.

Based on our findings early reports during outbreaks and pandemics should ideally describe consecutively enrolled, objectively defined but minimally selected patients to best inform appropriate clinical and policy decisions. These reports should be separate from publications reporting on selected populations. Such reports are important to identify risk factors for differential outcomes, but it is very important that such populations should be clearly defined. Such differentiation ensures an accurate and homogenous assessment of disease severity at a global scale. This allows for early recognition in differences in outcomes associated with disease outbreaks over different time periods and geographical regions when considering its impact at a global scale. Ideally this would be accomplished using prospectively developed, flexible and tiered case report forms that are appropriate for a variety of resource settings.[23]

Reporting on differences in regional outcomes associated with critical illness in a global context is challenging. The lack of standardized definitions, and differences in severity of disease recognized as critical illness have been cited as potential barriers. [24–26] When we compared differences in reported mortality based on early reporting compared to prolonged periods of enrollment for countries with available data, there was no difference in the reported mortality over time among countries, but country-specific differences in reported mortality persisted over time (Table 3). [7, 27–29] Our study highlights that the use of geographic variables such as hemispheres or continents is likely less sensitive to differences among regions as differential resources and patient characteristics can exist within broadly defined geographical units. The

| Subgroup                          | Studies (N) | Deaths (N) | Patients (Total, N) | Proportion Dead (95% CI) | p-value | I-squared |
|----------------------------------|-------------|------------|--------------------|-------------------------|---------|-----------|
| Specific Populations             |             |            |                    |                         |         |           |
| Unselected Critically Ill Patients | 72          | 2235       | 9312               | 27.0 [24.4, 29.9]       | <0.0001 | 80.4%     |
| Non-conventional Modes           | 12          | 117        | 355                | 34.1 [27.7, 41.1]       | 0.24    | 57.5%     |
| Mechanical Ventilation           | 31          | 460        | 1028               | 41.8 [35.7, 48.2]       | 0.31    | 63.1%     |
| Specific Subgroups               |             |            |                    |                         |         |           |
| Pregnant                         | 3           | 9          | 105                | 9.6 [4.5, 19.2]         | 0.22    | 82.5%     |
| ARDS                             | 37          | 318        | 838                | 37.4 [31.7, 43.4]       | 0.57    | 57.5%     |
| Acute Kidney Injury              | 4           | 33         | 74                 | 43.9 [26.1, 63.5]       | 0.57    | 57.6%     |
| Overall (no pediatrics)          | 115         | 2812       | 10695              | 30.9 [28.2, 33.7]       |         |           |

Fig 4. Differences in reported mortality based on subgroups of patients with different severity of illness (need for mechanical ventilation), critical illness associated organ failure (ARDS; AKI) or co-presenting conditions (pregnancy). The black squares represent the point estimate and 95% confidence intervals (CIs) around the mortality for each subgroup. The black diamond is the summary or overall combined estimate of mortality associated with the 2009 Influenza A (H1N1) pandemic.

doi:10.1371/journal.pone.0155044.g004
use of either economic development or geographic regions as defined by World Bank was more sensitive in demonstrating the impact on reported mortality. The economic development of the country might be a surrogate marker for the availability of ICU specific therapies, recognizing that substantial intra-country differences may exist among private and public systems.

Strengths of this systematic review include a comprehensive search strategy, with duplicate screening and outcome data abstraction, providing the most complete review of pandemic H1N1 outcomes to date. We used validated strategies to minimize bias in the selection of studies and reporting of outcomes and a priori planned the combinations of studies to report on different time periods of the pandemic, specific sub-groups and clinically important interventions. We used meta-regression to examine the impact of moderator variables on study effect size. We used random-effects models to aggregate data and generate conservative confidence limits for point estimates. We used the Newcastle-Ottawa scale to ensure we adequately recognized and reported the risk of bias. Although we included studies from all regions of the world, the majority of our outcomes were informed by developed regions with capacity to carry out observational and intervention research, and also, the capacity to provide tertiary care for these patients. Because most prior estimates of global mortality have used extrapolated mortality rates from high-income countries, it is quite possible that global pandemic-associated mortality is higher than previously reported. [12, 30]

Conclusions

In this systematic review of the published literature examining global patient characteristics and outcomes for H1N1-related critical illness during the 2009–2011 pandemic, we provide the most accurate and valid estimates of outcomes, and explore how these outcomes differ according to population, patient and study characteristics. Reported mortality for new outbreaks may vary substantially depending upon selected patient characteristics, the number of patients described, and the region and economic status of the outbreak location. These findings have relevance for new and ongoing outbreaks. Outbreaks should use case report forms that are prospectively developed, modifiable depending upon the illness syndrome, scalable to a variety of resource settings, encompass some measure of severity of illness to allow for risk adjustment across regions, and should be freely and globally available. [23] A standardized global approach to reporting on outbreaks and pandemics will provide us more accurate estimates of morbidity and mortality associated with new diseases and provide to the most valid information upon which to base current and future research, clinical care, and health systems responses.

Supporting Information

S1 File. Supplement for H1N1 global variability manuscript. Fig A: Flowchart for subgroups of studies analyzed in the meta-regression. Fig B: Funnel Plot. Fig C: Funnel Plot with Trim and fill effect revealing missing studies. Table A: System and study based characteristics described in 226 studies compared to the 115 studies selected for the meta-regression and 86 studies for the hierarchical model respectively. Table B: Differences in Mortality, Length of Stay in the ICU and duration of Mechanical ventilation based on the World Bank economic development classification. The Median (range) of the Newcastle-Ottawa scale for different groups of studies. Table C: Differences in baseline characteristics based on the studies only describing unselected critically ill patients, studies describing patients undergoing mechanical ventilation, and studies describing patients under consideration or actually getting ECMO. (DOCX)
S2 File. PRSIMA Checklist.

(DOC)

S3 File. Data Sheet for H1N1 global variability manuscript.

(XLSX)

Author Contributions
Conceived and designed the experiments: AD RP GR RF. Analyzed the data: AD RP RF. Wrote the paper: AD RP GR RF.

References
1. Levy MM, Baylor MS, Bernard GR, Fowler R, Franks TJ, Hayden FG, et al. Clinical issues and research in respiratory failure from severe acute respiratory syndrome. Am J Respir Crit Care Med. 2005; 171(5):518–26. Epub 2004/12/14. doi: 10.1164/rccm.200405-621WS PMID: 15591472.

2. Van Kerckhove MD, Vandemaele KA, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med. 2011; 8(7):e1001053. Epub 2011/07/14. doi: 10.1371/journal.pmed.1001053 PMID: 21750667; PubMed Central PMCID: PMC313021.

3. Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H, et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. N Engl J Med. 2014; 370(6):520–32. Epub 2013/04/26. doi: 10.1056/NEJMoa1304617 PMID: 23614499.

4. Fowler RA, Fletcher T, Fischer II WA, Lamontagne F, Jacob S, Brett-Major D, et al. Caring for Critically Ill patients with Ebola Virus Disease: Perspectives from West Africa. Am J Respir Crit Care Med. 2014. Epub 2014/08/29. doi: 10.1164/rccm.201408-1514CP PMID: 25166884.

5. Dominguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, de la Torre A, et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. Jama. 2009; 302(17):1880–7. Epub 2009/10/14. doi: 10.1001/jama.2009.1536 PMID: 19822626.

6. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009; 361(20):1935–44. Epub 2009/10/10. doi: 10.1056/NEJMoa0906695 PMID: 19815859.

7. Martin-Loeches I, Diaz E, Vidal L, Torres A, Laborda C, Granada R, et al. Pandemic and post-pandemic influenza A (H1N1) infection in critically ill patients. Crit Care. 2011; 15(6):R286. Epub 2011/12/01. doi: 10.1186/cc10573 PMID: 22126648; PubMed Central PMCID: PMC3386633.

8. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerckhove MD, Hollingsworth TD, et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science. 2009; 324(5934):1557–61. Epub 2009/05/13. doi: 10.1126/science.1176062 PMID: 19433588; PubMed Central PMCID: PMC3735127.

9. Estenssoro E, Rios FG, Apezteguia C, Reina R, Neira J, Cerasco DH, et al. Pandemic 2009 influenza A in Argentina: a study of 337 patients on mechanical ventilation. Am J Respir Crit Care Med. 2010; 182(1):41–8. Epub 2010/03/06. doi: 10.1164/ajrccm.201001-0037OC PMID: 20203241.

10. Davies A, Jones D, Bailey M, Beca J, Bellomo R, Blackwell N, et al. Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. Jama. 2009; 302(17):1888–95. Epub 2009/10/14. doi: 10.1001/jama.2009.1535 PMID: 19622628.

11. Intensive-care patients with severe novel influenza A (H1N1) virus infection—Michigan, June 2009. MMWR Morb Mortal Wkly Rep. 2009; 58(27):749–52. Epub 2009/07/18. PMID: 19609249.

12. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012; 12(9):687–95. Epub 2012/06/29. doi: 10.1016/S1473-3099(12)70121-4 PMID: 22738893.

13. Organization WH. Influenza Laboratory Surveillance System 08/12/2014 [cited 2014 July 18]. Available: gamapserver.who.int/gareports/Default.aspx?ReportNo = 6.

14. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264–9, W64. Epub 2009/07/23. PMID: 19622511.

15. Country and lending groups: The World Bank 2014 [cited 2014 30th March]. Available: http://data.worldbank.org/about/country-and-lending-groups.
16. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(8):603–5. Epub 2010/07/24. doi: 10.1007/s10654-010-9491-z; PMID: 20652370.

17. Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014; 14:45. Epub 2014/04/03. doi: 10.1186/1471-2288-14-45 PMID: 24690082; PubMed Central PMCID: PMC4021422.

18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177–88. Epub 1986/09/01. PMID: 3802833.

19. Montori VG, Oxman A, Cook D. Summarizing the evidence: Fixed-effects and random-effects models. In: Guyatt G RD, editor. Users’ Guide to the Medical Literature: A manual for evidence-based Clinical Practice. 2002. Chicago: AMA Press; 2002. p. 539–46.

20. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002; 21(11):1559–73. Epub 2002/07/12. doi: 10.1002/sim.1187 PMID: 12111920.

21. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002; 21(4):589–624. Epub 2002/02/12. PMID: 11836738.

22. Konstantopoulos S. Fixed effects and variance components estimation in three-level meta-analysis. Res Synth Methods. 2011; 2(1):61–76. Epub 2011/03/01. doi: 10.1002/jrsm.35 PMID: 22606160.

23. ISARIC. The Global Health Netwerk - Protocols and Data tools 2014 [December 20th, 2014]. Available: https://isaric.tghn.org/protocols/.

24. Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD. Critical care and the global burden of critical illness in adults. Lancet. 2010; 376(9749):1339–46. Epub 2010/10/12. doi: 10.1016/S0140-6736(10)60446-1; PMID: 20934212.

25. Adhikari NK, Rubenfeld GD. Worldwide demand for critical care. Curr Opin Crit Care. 2011; 17(6):620–5. Epub 2011/11/10. doi: 10.1097/MCC.0b013e32834cd39c PMID: 22067878.

26. Fowler RA, Adhikari NK, Bhagwanjee S. Clinical review: critical care in the global context—disparities in burden of illness, access, and economics. Crit Care. 2008; 12(5):225. Epub 2008/11/19. doi: 10.1186/cc6984; PubMed Central PMCID: PMC2592728.

27. Rice TW, Rubinson L, Uyeki TM, Vaughn FL, John BB, Miller RR 3rd, et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med. 2012; 40(5):1467–98. Epub 2012/04/19. doi: 10.1097/CCM.0b013e3182416243; PMID: 22511131; PubMed Central PMCID: PMC3653183.

28. Muscedere J, Orlner M, Kumar A, Long J, Lamontagne F, Cook D, et al. The occurrence and impact of bacterial organisms complicating critical care illness associated with 2009 influenza A(H1N1) infection. Chest. 2013; 144(1):39–47. Epub 2013/02/09. doi: 10.1378/chest.12-1861 PMID: 23392627.

29. Webb SA, Aubron C, Bailey M, Bellomo R, Howe B, McArthur C, et al. Critical care services and the H1N1 (2009) influenza epidemic in Australia and New Zealand in 2010: the impact of the second winter epidemic. Crit Care. 2011; 15(3):R143. Epub 2011/06/11. doi: 10.1186/cc10266; PMID: 21658233; PubMed Central PMCID: PMC3219015.

30. Simonsen L, Spreeuwenberg P, Lustig R, Taylor RJ, Fleming DM, Kroneman M, et al. Global mortality estimates for the 2009 Influenza Pandemic from the GLaMOR project: a modeling study. PLoS Med. 2013; 10(11):e1001558. Epub 2013/12/05. doi: 10.1371/journal.pmed.1001558; PMID: 24302890; PubMed Central PMCID: PMC3841239.